What if you could get more data from your off-target screening, not only WHERE your off-target occurred, but also WHAT protein caused it?
View this webinar to see case studies that utilized technology trailblazers, IHC and Retrogenix Cell Microarray to achieve this distinction. You will learn how the robust output:
- Informs lead candidate selection and safety assessment
- Increases process efficiency and enhances regulatory submissions
- Identifies and mitigates the risk of clinical toxicity caused by off-target effects
Brad Gartland, BSc
Senior Client Manager
Shari Price, PhD
DABT, Senior Research Pathologist
We are providing digital education options to keep you learning about topics you may be interested in. For more information, visit criver.com/digital-education.